<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-07T14:21:29Z</responseDate>
  <request identifier="oai:figshare.com:article/33785824" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33785824</identifier>
        <datestamp>2026-09-15T11:18:13Z</datestamp>
        <setSpec>category_24676</setSpec>
        <setSpec>category_24685</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Rationally modified-CaCO&lt;sub&gt;3&lt;/sub&gt; carriers for prolonged drug release and radionuclide retention in combination chemo-radionuclide therapy</dc:title>
          <dc:creator>Darya Akhmetova (24926425)</dc:creator>
          <dc:creator>Alexander Timin (19691560)</dc:creator>
          <dc:subject>Nanomedicine</dc:subject>
          <dc:subject>Medical biotechnology not elsewhere classified</dc:subject>
          <dc:subject>calcium carbonate</dc:subject>
          <dc:subject>drug delivery systems</dc:subject>
          <dc:subject>prolonged release</dc:subject>
          <dc:subject>retention</dc:subject>
          <dc:subject>radionuclide therapy</dc:subject>
          <dc:subject>chemotherapy</dc:subject>
          <dc:subject>combined therapy</dc:subject>
          <dc:description>&lt;p dir="ltr"&gt;Here, we designed optimal conditions for high drug loading efficiency of 2AT and &lt;sup&gt;223&lt;/sup&gt;Ra with mutually improving therapeutic mechanisms of chemotherapy and α-radionuclide therapy. Importantly, the incorporation of 2AT and radiolabeling with &lt;sup&gt;223&lt;/sup&gt;Ra resulted in a slower dissolution of the CaCO&lt;sub&gt;3&lt;/sub&gt; microparticles compared with the unloaded carrier. The resulting changes in carrier dissolution contribute to prolonged retention of the therapeutic components and provide sustained local exposure following intratumoral administration. The developed microparticles were comprehensively characterized, and their stability and release behavior were evaluated under different pH conditions. Their interaction with B16-F10 cells was investigated &lt;i&gt;in vitro&lt;/i&gt;, while biodistribution, antitumor efficacy, and biosafety were evaluated in a murine solid tumor model. This study demonstrates the potential of controlling the physicochemical behavior of a CaCO&lt;sub&gt;3&lt;/sub&gt; carrier through incorporation of chemically distinct therapeutic components to achieve prolonged local co-delivery of a chemotherapeutic agent and &lt;sup&gt;223&lt;/sup&gt;Ra.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-15T11:18:13Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.6084/m9.figshare.33785824.v1</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/Rationally_modified-CaCO_sub_3_sub_carriers_for_prolonged_drug_release_and_radionuclide_retention_in_combination_chemo-radionuclide_therapy/33785824</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
